Pages that link to "Q34519377"

The following pages link to The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot (Q34519377):

Displaying 35 items.

• The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors (Q24605967) (← links)
• Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism (Q28084069) (← links)
• c-Fos identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat. (Q33725056) (← links)
• In vivo pharmacology of the dopaminergic stabilizer pridopidine (Q34128435) (← links)
• Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor (Q34134875) (← links)
• II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors (Q34210759) (← links)
• I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors (Q34211486) (← links)
• Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro (Q34646377) (← links)
• Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization (Q34763003) (← links)
• Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? (Q35012574) (← links)
• The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects (Q35647369) (← links)
• The effects of the dopamine stabilizer (-)-OSU6162 on aggressive and sexual behavior in rodents (Q36915486) (← links)
• A decade of progress in the discovery and development of 'atypical' antipsychotics (Q37790485) (← links)
• Dopamine and Huntington's disease. (Q38379277) (← links)
• Pridopidine for the treatment of Huntington's disease (Q38735562) (← links)
• Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model (Q38861728) (← links)
• Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date (Q40277912) (← links)
• Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses (Q40753593) (← links)
• Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease (Q41196024) (← links)
• The monoamine stabilizer (-)-OSU6162 counteracts downregulated dopamine output in the nucleus accumbens of long-term drinking Wistar rats (Q41392387) (← links)
• The dopaminergic stabilizer pridopidine increases neuronal activity of pyramidal neurons in the prefrontal cortex (Q42435280) (← links)
• The pridopidine paradox in Huntington's disease (Q45294030) (← links)
• Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: a double-blind cross-over study (Q45301837) (← links)
• Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. (Q45305901) (← links)
• The Effects of the Monoamine Stabilizer (-)-OSU6162 on Binge-Like Eating and Cue-Controlled Food-Seeking Behavior in Rats (Q47321455) (← links)
• Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease (Q47694898) (← links)
• The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression (Q51088282) (← links)
• Pridopidine Reverses Phencyclidine-Induced Memory Impairment. (Q52564664) (← links)
• The monoamine stabilizer (-)-OSU6162 prevents the alcohol deprivation effect and improves motor impulsive behavior in rats. (Q52685500) (← links)
• Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease. (Q52685691) (← links)
• Effects of the monoamine stabilizer (-)-OSU6162 on locomotor and sensorimotor responses predictive of antipsychotic activity. (Q53731838) (← links)
• The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor (Q60049913) (← links)
• The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans (Q83593827) (← links)
• Effects of the dopamine stabilizers (S)-(-)-OSU6162 and ACR16 on prolactin secretion in drug-naive and monoamine-depleted rats (Q84010902) (← links)
• Effect of the dopamine stabilizer (-)-OSU6162 on potentiated incubation of opioid craving after electric barrier-induced voluntary abstinence (Q92439426) (← links)